Neuronal vulnerability following inhibition of mitochondrial complex II: A possible ionic mechanism for Huntington's disease

Molecular and Cellular Neuroscience

Volumn 25, Issue 1, 2004, Pages 9-20

  Saulle, Emilia ^a,b   Gubellini, Paolo ^a,c   Picconi, Barbara ^a,b   Centonze, Diego ^a,b   Tropepi, Domenicantonio ^a,b   Pisani, Antonio ^a,b   Morari, Michele ^d   Marti, Matteo ^d   Rossi, Luisa ^e   Papa, Michele ^f   Bernardi, Giorgio ^a,b   Calabresi, Paolo ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TYPE; CONTROLLED STUDY; GENETIC SUSCEPTIBILITY; HUNTINGTON CHOREA; HYPERPOLARIZATION; INTERNEURON; MEMBRANE DEPOLARIZATION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRIATE CORTEX; WILD TYPE;

MUS MUSCULUS;

EID: 10744226789     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2003.09.013     Document Type: Article

References (59)

1. Alexi T., Hughes P.E., Knusel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/cByJ mice. Exp. Neurol. 153:1998;74-93.
2. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
3. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivasta R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13:1993;4181-4192.
4. Beani L., Bianchi C., Giacomelli A., Tamberi F. Noradrenaline inhibition of acetylcholine release from guinea-pig brain. Eur. J. Pharmacol. 48:1978;179-193.
5. Beherens M.I., Koh J., Canzoniero L.M., Sensi S.L., Csernansky C.A., Choi D.W. 3-Nitropropionic acid induces apoptosis in cultured striatal and cortical neurons. NeuroReport. 6:1995;545-548.
6. Bogdanov M.B., Ferrante R.J., Kuemmerle S., Klivenyi P., Beal M.F. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J. Neurochem. 71:1998;2642-2644.
7. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willing A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7105-7109.
8. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.K., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:1997;646-653.
9. Calabresi P., Centonze D., Pisani A., Bernardi G. Endogenous adenosine mediates the presynaptic inhibition induced by aglycemia at corticostriatal synapses. J. Neurosci. 17:1997;4509-4519.
10. Calabresi P., Magarinos Ascone C., Centonze D., Pisani A., Sancesario G., D'Angelo V., Bernardi G. Opposite membrane potential changes induced by glucose deprivation in striatal spiny neurons and cholinergic interneurons. J. Neurosci. 17:1997;1940-1949.
11. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Ann. Neurol. 43:1998;586-597.
12. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23:2000;120-126.
13. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci. 21:2001;5110-5120.
14. Calabresi P., Saulle E., Marfia G., Centonze D., Mulloy R., Picconi B., Hipskind R.A., Conquet F., Bernardi G. Activation of metabotropic glutamate receptor subtype1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. Mol. Pharmacol. 60:2001;808-815.
15. Cattaneo E., Calabresi P. Mutant huntingtin goes straight to the heart. Nat. Neurosci. 5:2002;3-4.
16. Centonze D., Saulle E., Pisani A., Bernardi G., Calabresi P. Adenosine-mediated inhibition of striatal GABAergic synaptic transmission during in vitro ischaemia. Brain. 124:2001;1855-1875.
17. Cicchetti F., Prensa L., Wu Y., Parent A. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Rev. 34:2000;80-101.
18. Damsma G., Lammerts van Bueren D., Westerink B.H.C., Horn A.S. Determination of acetylcholine and choline in the femtomole range by means of HPLC, a post-column enzyme reactor and electrochemical detection. Chromatographia. 24:1987;827-831.
19. Davies J.A. Remacemide hydrochloride: a novel antiepileptic agent. Gen. Pharmacol. 28:1997;499-502.
20. Dyker A.G., Lees K.R. Remacemide hydrochloride: a double-blind, placebo controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 30:1999;1796-1801.
21. Ferrante R.J., Kowall N.J., Beal M.F., Richardson E.P., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 320:1985;561-563.
22. Graybiel A.M. Building action repertories: memory and learning function of the basal ganglia. Curr. Opin. Neurobiol. 5:1995;733-741.
23. Greene J.G., Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
24. Greene J.G., Porter R.H., Eller R.V., Greenamyre J.T. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J. Neurochem. 61:1993;1151-1154.
25. Greene J.G., Sheu S.-S., Gross R.A., Greenamyre J.T. 3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience. 84:1998;503-510.
26. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
27. Hickey M.A., Morton A.J. Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. J. Neurochem. 75:2000;2163-2171.
28. Hollander M., Wolfe D.A. Nonparametric Statistical Methods. 1973;Wiley, New York.
29. Kawaguchi Y., Wilson C.J., Augood S.J., Emson P.C. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci. 18:1995;527-535.
30. Kieburtz K., Feigin A., McDermott M., Como P., Abwender D., Zimmerman C., Hichey C., Orme C., Claude K., Sotack J., Greenamyre J.T., Dunn C., Shoulson I. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 11:1996;273-277.
31. Kim G.W., Copin J.-C., Kawase M., Chen S.F., Sato S., Gobbel G.T., Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20:2000;119-129.
32. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.-F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease mice. J. Neurophysiol. 86:2001;2667-2677.
33. Kornhauser J.M., Greenberg M.E. A kinase to remember: dual roles for MAP kinase in long-term memory. Neuron. 18:1997;839-842.
34. Kurino M., Fukunaga K., Ushio Y., Miyamoto E. Activation of mitogen-activated protein kinase in cultured rat hippocampal neurons by stimulation of glutamate receptors. J. Neurochem. 65:1995;1282-1289.
35. La Fontaine M.A., Geddes J.W., Banks A., Butterfield D.A. 3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res. 858:2000;356-362.
36. Lindroth P., Mopper K. High performance liquid chromatographic determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phtaldehyde. Anal. Chem. 51:1979;1667-1674.
37. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:1991;492-498.
38. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
39. McKee P., Fuller G.N., Stevens D.L. Riluzole in amiotrophic lateral sclerosis. N. Engl. J. Med. 331:1994;272.
40. McMurray C.T. Huntington's disease: new hope for therapeutics. Trends Neurosci. 24:2001;S32-S38. (Suppl.).
41. Mitchell I.J., Cooper A.J., Griffitths M.R. The selective vulnerability of striatopallidal neurons. Prog. Neurobiol. 59:1999;691-719.
42. Murphy A.N., Fiskum G., Beal M.F. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J. Cereb. Blood Flow Metab. 19:1999;231-245.
43. Palfi S., Ferrante R.J., Brouillet E., Beal M.F., Dolan R., Guyot M.C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16:1996;3019-3025.
44. Parkinson Study Group A multicenter randomised controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology. 54:2000;1583-1588.
45. Price D.L., Sisodia S.S., Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 282:1998;1079-1083.
46. Reddy P.H., Williams M., Tangle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci. 22:1999;248-255.
47. Reynolds D.S., Carter R.J., Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 18:1998;10116-10127.
48. Riepe M., Hori N., Ludolph A.C., Carpenter D.O., Spencer P.S., Allen C.N. Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels. Brain Res. 17:1992;61-66.
49. Sato S., Gobbel G.T., Honkaniemi J., Li Y., Kondo T., Murakami K., Sato M., Copin J.-C., Sharp F.R., Chan P.H. Decreased expression of bcl-2 and bcl-x mRNA coincides with apoptosis following intracerebral administration of 3-nitropropionic acid. Brain Res. 808:1998;56-64.
50. Schmued L.C., Albertson C., Slikker W. Jr. Fluoro-Jade B: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 751:1997;37-46.
51. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174:1997;193-197.
52. Shapira A.H.V. Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta. 1366:1998;225-233.
53. Song J.-H., Huang C.-S., Nagata K., Yeh J.Z., Narahashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J. Pharmacol. Exp. Ther. 282:1997;707-714.
54. Tabrizi S.J., Cleeter M.W.J., Xuereb J., Taanman J.-W., Cooper J.M., Shapira A.H.V. Biochemical abnormalities and excitotoxicity in Huntington's disease. Ann. Neurol. 45:1999;25-32.
55. Tavares R.G., Santos C.E., Tasca C.I., Wajner M., Souza D.O., Dutra-Filho C.S. Inhibition of glutamate uptake into synaptic vesicles from rat brain by 3-nitropropionic acid in vitro. Exp. Neurol. 172:2001;250-254.
56. Taylor R.W., Birch-Machin M.A., Bartlett K., Turnbull D.M. Succinate-cytochrome c reductase: assessment of its value in the investigation of the respiratory chain. Biochim. Biophys. Acta. 1181:1993;261-265.
57. Thornberry N.A., Lazbnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
58. Wullner U., Young A.B., Penney J.B., Beal M.F. 3-Nitropropionic acid toxicity in the striatum. J. Neurochem. 63:1994;1772-1781.
59. Xia Z., Dudek H., Miranti C.K., Greenberg M.E. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J. Neurosci. 16:1996;5425-5436.